Phase 2 study of ET-743 as second or third line therapy in advanced and/or metastatic soft tissue sarcoma patients Posted on March 15, 2018 by tsuperadmin -
Phase II study on ET-743 in advanced soft tissue sarcomas of the adult (excluding gastrointestinal stroma cell tumors – GIST) Posted on March 15, 2018 by tsuperadmin -
NCT00207714 – A Randomized, Double-blind, Dose-ranging Trial of CNTO 148 Subcutaneous Injection Compared With Placebo in Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Posted on March 15, 2018 by tsuperadmin -
NCT01483599 – A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE) Posted on February 27, 2018 by tsuperadmin -
NCT01497119 – A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-39758979 in Adult Japanese Subjects with Moderate Atopic Dermatitis Posted on January 30, 2018 by tsuperadmin -
NCT00267956 – A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Posted on January 29, 2018 by tsuperadmin -
NCT00266617 – The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Chemotherapy Posted on November 10, 2017 by tsuperadmin -
NCT00269997 – The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Cisplatin Chemotherapy Posted on November 10, 2017 by tsuperadmin -
NCT01340664 – A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Posted on October 26, 2017 by tsuperadmin -
A group comparative, placebo-controlled, double-blind trial of the efficacy and safety of galantamine hydrobromide, 7.5 mg (6 mg galantamine base) TID, 10 mg (8 mg galantamine base) TID and 15 mg (12 mg galantamine base) TID taken orally for 12 weeks in patients with a diagnosis of senile dementia of the Alzheimer’s type Posted on October 13, 2017 by tsuperadmin -
The YODA Project